10
Participants
Start Date
October 31, 2011
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
BEZ235
"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
Memorial Sloan Kettering Cancer Center, New York
Collaborators (1)
Novartis
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER